Amyloidosis: A global problem common in Papua New Guinea

Papua and New Guinea Medical Journal

Volumn , Issue 4, 1996, Pages 284-296

  McAdam, Keith P W J ^a,e   Raynes, John G ^b   Alpers, Michael P ^a   Wermark, Gunilla T ^c   Westermark, P E R ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Guinea)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; SERUM AMYLOID A;

AMYLOIDOSIS; GENETICS; HEALTH; HUMAN; MUTATION; PAPUA NEW GUINEA; REVIEW;

AMYLOID; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; HUMANS; MUTATION; PAPUA NEW GUINEA; SERUM AMYLOID A PROTEIN; WORLD HEALTH;

EID: 0030308198     PISSN: 00311480     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Husby G, Araki S, Benditt EP, Bcnson MD, Cohen AS, Frangione B, Glenner GG, Naivig JB, Westermark P. Nomenclature of amyloid and arayloiuosis. Bull World Health Organ 1993;71:105-108.
2. Cooke RA, Champness LT. Renal disease and goitre: a new syndrome of primary amyloidosis. Aust Paediatr J 1972;8:250-254.
3. Anders RF, Price MA, Wilkey IS, Husby G, Takitaki F, Natvig JB, McAdam KPWJ. Amyloid fibril profein AA in Papua New Guinean amyloidosis. Clin Exp Immmol 1976;24:49-53.
4. Anders RF, Price MA, Wilkey IS. Geographical distribution of amyloidosis in Papua New Guinea. Trop Geogr Med 1976;28:273-282.
5. McAdam KPWJ, Anders RF, Smith SR, Russell DA, Price MA. Association of amyloidosis with erythema nodosum leprosurn reactions and recurrent neutrophil leukocytosis in leprosy. Lancet 1975;2:572-576.
6. Cooke RA, Champness LT. Amyloidosis in Papua New Guinea. Med J Aust 1970;2:1177-1184.
7. McAdam KPWJ. Leprosy, filariasis and malaria as causes of secondary amyloidosis in the tropics. PNG Med J 1978;21:69-78.
8. McAdam KPWJ, Westermark P, Anders RF, Voller A. Juvenile amyloidosis in the Anga peoples of Papua New Guinea. In: Glenner GG, Costa PP, deFreitas AF, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica & North-Holland, 1980:207-210.
9. Crane GG, Pryor DS. Malaria and the tropical splenomegaly syndrome in New Guinea. Trans R Soc Trop Med Hyg 1971:65:315-324.
10. Crane GG, Hudson P, Hudson BET. The effect of suppressive antimalarial therapy in tropical splenomegaly syndrome in New Guineans. PNG Med J 1973; 16:46-50.
11. Bryceson ADM, Fakunle YM, Fleming AF, Crane GG, Hutt MSR, De Cock KM, Greenwood BM, Marsden PD, Rees P. Malaria and splenomegaly. Trans R Soc Trop Med Hyg 1983:77:879.
12. Serjeantson SW, Crane GG. Analysis of the patterns of inheritance of splenomegaly and serum IgM levels in the Watut of Papua New Guinea. Hum Biol 1991:63:115-128.
13. Bhatia KK, Crane GG. HLA heterozygosity and hyperreactive malarious splenomegaly in the Upper Watut Vallev of Papua New Guinea. PNG Med J 1939:32:277-286.
14. Huffman SL, Piessens WF, Ratiwayanto S, Hussein PR, Kurniawan L, Piessens PW, Campbell JR, Marwoto HA. Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med 1984:310:337-341.
15. Ziegler JL. Cryoglobulinaemia in tropical splenomegaly syndrome. Clin Exp Immunol 1973:15:65-78.
16. Fakunle YM, Greenwood BM. Metabolism of IgM in the tropical splenomegaly syndrome. Trans R Soc Trop Med Hyx 1976;70:346-348.
17. Crane G, Gibson D, Verrall J, Barker-Hudson P, Barker-Hudson BET, Charlwood D, Heywood P. Malaria and tropical splenomegaly syndrome in the Anga of Morobe Province. PNG Med J 1985:28:27-34.
18. Westermark P, Stenkvist B. A new method for the diagnosis of systemic ainyloidosis. Arch intern Med 1973:132:522-523.
19. Alpers MP. Kuru. In: Attenborough RD, Alpers MP, eds. Human Biology in Papua New Guinea: The Small Cosmos. Oxford: Clarendon Press, 1992:313-334.
20. Bolton DC, McKiniey MP, Prusiner SB. Identification of a protein that purifies with the scrapie prion. Science 1992;218:1309-1311.
21. Gajdusek DC, Gibbs CJ Jr, Alpers M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 1966;209:794-796.
22. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982:216:136-144.
23. Brown P. The "brave new world" of transmissible spongiform encephalopathy (infectious cerebral amyioidosis). Mol Neurobiol 1994;8:79-87.
24. Paunio T. Molecular pathogenesis of familial amyioidosis, Finnish type. PhD Thesis, University of Helsinki, 1995.
25. Glenner GG. Amyloid deposits and amyioidosis: the ß-fibrilloses. N Engl J Med 1980:302:1283-1292, 1333-1343.
26. Beeker JW, Reeke GN Jr. Three-dimensional structure of beta2-microglobulin. Proc Natl Acad Sci USA 1985;82:4225-4229.
27. Blake CCF, Geisow MJ, Oatiey SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 1978;121:339-356.
28. 1. Presumptive identification of calcium and lipid binding sites. Mol Biol Med 1986;3:387-407.
29. Wetzel R. Mutations and off-pathway aggregation of proteins. Trends Biotechnol 1994:12:193-198.
30. Gustavsson Å, Engström U, Westermark P. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 1994:144:1301-1311.
31. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992:31:8654-8660.
32. Jarvis JA, Munro SLA, Craik DJ. Structural analysis of peptide fragment 71-93 of transthyretin by NMR spectroscopy and electron microscopy: insight into amyloid fibril formation. Biochemistry 1994;33:33-41.
33. Jarrett JT, Lansbury PT Jr. Seeding. "One-dimensionai crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-1058.
34. Jarrett JT, Berger DP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-4697.
35. Naiki H, Higuchi K, Nakakuki K, Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 1991:65:104-110.
36. Prusiner SB, DeArmond SJ. Prion diseases and neurodegeneration. Annu Rev Neurosci 1994:17:311-339.
37. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M. Further characterization of amyloidenhancing factor. Lab Invest 1982:47:139-146.
38. Niewold TA, Hol PR, van Andel ACJ, Lutz ETG, Gruys E. Enhancement of amyloid induction by amyloid fibril fragments in hamster. Lab Invest 1987;56:544-549.
39. Ganowiak K, Hultman P, Engström U, Gustavsson A, Wesicrmark P. Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 1994;199:306-312.
40. Schwalbe RA, Dahlbäck B, Coe JE, Nelsestuen GL. Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethano lamine. Biochemistry 1992:31:4907-4915.
41. Dyck RF. Lockwood CM, Kershaw M. McHugh X, Duance VC, Baltz ML, Pepys MB. Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med 1980:152:1162-1174.
42. Breathnach SM, Pepys MB, Hintner H. Tissue amyloid P component in normal human dermis is non-covalently associated with elastic fiber microfibrils. J Invest Dermaiol 1989:92:53-58.
43. Skinner M, Shirahama T, Cohen AS, Deal CL. The association of amyloid P-component (AP) with the amyloid fibril: an updated method for amyloid fibril protein isolation. Prep Biochem 1982:12:461-476.
44. Pepys MB, Butier PJG. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 1987:148:308-313.
45. Li JJ, McAdam KPWJ. Human amyloid P component: an elastase inhibitor. Scand J Immunol 1984:20:219-226.
46. Vachino G, Heck LW, Gelfand JA, Kaplan MM, Burke JF, Berninger RW, McAdam KPWJ. Inhibition of human neutrophil and pseudomonas elastases by the amyloid P-component: a constituent of elastic fibers and amyloid deposits. J Leukoc Biol 1988:44:529-534.
47. Nelson SR, Lyon M, Gailagher JT, Johnson EA, Pepys MB. isolation ana characterization of the integral glycosaminoglycan constituents of human amyloid A and monocional light-chain amyloid fibrils. Biochem J 1991;275:67-73.
48. Stenstad T, Magnus JH, Kolset SO, Cornwell GGI, Husby G. Macromolecidar properties of giycosaminoglycaris in primary AL amyloid fibril extracts of lymphoid tissue origin. Scand J Immunol 1991;34:611-617.
49. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R. A temporal and utrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 1991:39:1321-1330.
50. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 1988:256:775-783.
51. Lyon AW, Narindrasorasak S, Young ID, Anastassiades T, Couchman JR, McCarthy KJ, Kisilevsky R. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab invest 1991:64:785-790.
52. Westermark GT, Norling B, Westermark P. Fibronectin and basement membrane components in renal amyloid deposits in patients with primary and secondary amyloidosis. Clin Exp Immunol 1991:86:150-156.
53. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992:135:235-238.
54. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak Vance MA. Gene dose cf apoiipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993:261:921-923.
55. Strittmatter WJ, Welsgraber KH, Huang DY, Dong LM, Saivesen GS, Pericak Vance MA, Schmechel DE, Saunders AM, Goidgaber D, Roses AD. Binding of human apoiipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheiraer disease. Proc Nail Acad Sei USA 1993;90:83988102.
56. Kamboh MI, Bhaiia KK, Ferrell RE. Genetic studies of human apolipoproteins: XII. Population genetics of apolipoproteins in Papua New Guinea. Am J Hum Biol 1990;2:17-23.
57. Bausserman IX, Bernier DN, McAdam KPWJ, Herbert PN. Serum amyloid A and high density iipoproteins during the acme phase response. Eur J Clin Invest 1988:18:619-626.
58. McAdam KPWJ, Elin RJ, Sipe JD, Wolff SM. Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. J Clm Invest 1978;61:390-394.
59. Whitehead AS, de Beer MC, Steel DM, Rite M, Lelias JM, Lane WS, de Beer FC. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 1992:267:3862-3866.
60. Rokita H, Shirahama T, Cohen AS, Meek RL, Benditt EP, Sipe JD, Differential expression of the SAA 3 gene in liver and peritoneal macrophages of mice undergoing dissimilar inflammatorv episodes. J Immunol 1987:139:3849-3853.
61. Hoffman JS, Ericsonn LH, Eriksen N, Walsh KA, Benditt EP. Murine tissue amyloid protein AA. NH2-terminal sequence identity with only one of two serum amyloid protein (ApoSAA) gene products. J Exp Med 1984; 159:641-646.
62. Rsynes JG, Hultquist R, Molyneux M, Griffin G, McAdam KPWJ. SAA isoforms in patients with secondary amyloidosis. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P, eds. Proceedings of the Sixth International Conference on Amyloidosis, Oslo. Netherlands: Kluwer Academic Publishers, 1990:119-123.
63. Faulkes DJ, Betts JC, Woo P. Characterization of five human serum amyloid Ai alleles. Amyloid 1994:1:255-262.
64. Gauidie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 21 B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Nail Acad Sei USA 1987:84:7251-7256.
65. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Faniuzzi G, Ghezzi P, Poli V. Defective inflammatory response in interleukin-6-deficient mice. J Exp Med 1994; 180:1243-1250.
66. Raynes JG, Eagling S, McAdam KPWJ. Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 1991:83:488-491.
67. McAdam KPWJ, Dinarello CA. Induction of serum amyloid A synthesis by human leukocytic pyrogen. In: Agarwal MK, ed. Bacterial Endotoxins and Host Response. Amsterdam: Elsevier & North-Holland, 1980:167-177.
68. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo ?. The role of NF-kappaB and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993:268:25624-25631.
69. McGuire W, Hill AYS, Allsopp CEM, Greenwood BM, Xwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994:371:508-510.
70. Elkelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994;15:447-450.
71. Griffin WST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Nail Acad Sei USA 1989:86:7611-7615.
72. Lyon AW, Anastassiades T, Kisilevsky R. In vivo analysis of murine serum sulfate metabolism and splenic glycosaminogiycan biosynthesis during acute inflammation and amyloidosis. J Rheumatol 1993:20:1108-1113.
73. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today 1993:14:500-505.
74. Coe JE, Ross MJ. Amyloidosis and female protein in the Syrian hamster. Concurrent regulation by sex hormones. J Exp Med 1990:171:1257-1267.
75. jensson O, Bjornsson OG, Arnason A, Birgisdottir B, Pepys MB. Serum amyloid P-component and C-reactive protein in serum of healthy Icelanders and members of an Icelandic family with macroglobulinaemia. Acta Med Scand 1982:211:341-345.
76. Dersimonian H, McAdam KPWJ, Mackworth-Young C, Stollar BD. The recurrent expression of variable region segments in human IgM anti-DNA autoantibodies. }Immunol 1989;142:4027-4033.
77. McAdam KPWJ, Wheeler PR, Raynes JG, Duggan D. Serum amyloid P component shares binding similarities with a polyreactive germ line IgM autoantibody (the TH3 idiotype). In: Kisilevsky R, Gauldie J, Benson MD, Muckle TJ, Frangione B, Young ID, eds. Proceedings of the Seventh International Symposium on Amyloidosis. Kingston: Parthenon, 1993:171-175.